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Different Clinical Characteristics Among Aeromonas hydrophila, 
Aeromonas veronii biovar sobria and Aeromonas caviae 
Monomicrobial Bacteremia
This study aimed to compare the clinical presentations of Aeromonas hydrophila, A. veronii 
biovar sobria and A. caviae monomicrobial bacteremia by a retrospective method at three 
hospitals in Taiwan during an 8-yr period. There were 87 patients with A. hydrophila 
bacteremia, 45 with A. veronii biovar sobria bacteremia and 22 with A. caviae bacteremia. 
Compared with A. hydrophila and A. veronii biovar sobria bacteremia, A. caviae 
bacteremia was more healthcare-associated (45 vs 30 and 16%; P = 0.031). The patients 
with A. caviae bacteremias were less likely to have liver cirrhosis (27 vs 62 and 64%; 
P = 0.007) and severe complications such as shock (9 vs 40 and 47%; P = 0.009) and 
thrombocytopenia (45 vs 67 and 87%; P = 0.002). The APACHE II score was the most 
important risk factor of Aeromonas bacteremia-associated mortalities. The APACHE II 
scores of A. caviae bacteremias were lower than A. hydrophila bacteremia and A. veronii 
biovar sobria bacteremia (7 vs 14 and 16 points; P = 0.002). In conclusion, the clinical 
presentation of A. caviae bacteremia was much different from A. hydrophila and 
A. veronii biovar sobria bacteremia. The severity and mortality of A. caviae bacteremia 
were lower than A. hydrophila or A. veronii biovar sobria bacteremia.
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INTRODUCTION
Aeromonas is a kind of oxidase-producing gram-negative rods 
and belongs to the family Aeromonadaceae. It is widely distrib-
uted globally in aquatic environments and associated with a va-
riety of human infections, including gastroenteritis, soft tissue 
infection, septicemia, hepatobiliary tract infections, and occa-
sionally pleuropulmonary infections, indwelling-device related 
infections, meningitis, peritonitis, and hemolytic uremic syn-
drome (1). Although this pathogen could infect healthy persons, 
most infections were found in immunocompromised hosts, es-
pecially those with liver cirrhosis and malignancies (1-4). The 
possible pathogenesis of Aeromonas infection is complex and 
multifactorial. The possible portals of entry for Aeromonas bac-
teremia were considered as gastrointestinal tracts and skin le-
sions (1-5). After the adhesion to the epithelial cells of the intes-
tine, this pathogen produces many potential virulence factors 
to destroy epithelial barrier and impair immune cells, including 
exoenzymes, cytotoxic and cytotonic enterotoxins (6, 7). 
  Among 21 Aeromonas species differentiated on the basis of 
DNA-DNA hybridization, Aeromonas caviae, Aeromonas vero-
nii biovar sobria and Aeromonas hydrophila are most associat-
ed with human infections and amount for  > 85% of all clinical 
isolates (2-5). They have different biochemical properties (8, 9) 
and antimicrobial susceptibilities (10, 11). In addition, different 
Aeromonas species produce different virulence factors (12). How-
ever, it is unknown whether different Aeromonas species con-
tribute different clinical presentations. Here, we conducted a 
retrospective study to compare clinical presentations of the bac-
teremias caused by different Aeromonas species.
MATERILAS AND METHODS
This is a retrospective study, in which the patients diagnosed with 
monomicrobial Aeromonas bacteremia were admitted at Bud-
dhist Tzu Chi General Hospital, Buddhist Dalin Tzu Chi General 
Hospital and Buddhist Taipei Tzu Chi General Hospital (Taiwan) 
from January 2001 to November 2008. Buddhist Tzu Chi Gener-
al Hospital is a 700-bed tertiary referral medical center locating 
in Eastern Taiwan with special units for bone marrow and organ 
transplantation, burn care and intensive care. Buddhist Dalin 
Tzu Chi General Hospital and Buddhist Taipei Tzu Chi General 
Hospital are 900-bed regional teaching hospitals locating in 
Southern Taiwan and Northern Taiwan. The demographic, clin-Chuang H-C, et al.  •  Aeromonas Bacteremia
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ical and laboratory information were retrieved from the medi-
cal charts of the included patients for analysis.
  Aeromonas bacteremia was defined as growth of an Aeromo-
nas sp. from a blood culture of a patient with sepsis. Bacteremia 
was considered healthcare-associated if an Aeromonas isolate 
was obtained from blood sampled after more than 72 hr of hos-
pitalization in a patient who had been asymptomatic for infec-
tion upon admission, or from a patient who had received anti-
neoplastic chemotherapy in the preceding 2 weeks after draw-
ing blood for culture, regardless of symptomatology at admis-
sion. Aeromonas-involved polymicrobial bacteremia defined as 
simultaneous growth of an Aeromonas sp. and other microbe(s) 
from a blood culture of a patient with sepsis were excluded from 
this study. Death was considered to be attributable to Aeromo-
nas bacteremia if, during the same hospital stay, death occurred 
within 7 days after a positive blood culture for Aeromonas bacte-
remia without other cause for death, death occurred in the pres-
ence of clinical evidence of persistent sepsis, or the cause of death 
as recorded on the death certificate was Aeromonas bacteremia. 
Survivor from Aeromonas bacteremia was defined as if the pa-
tient was discharged alive or an improvement of bacteremia-as-
sociated symptoms occurred in the absence of recurrence with-
in 30 days during the same hospital stay.
  According to the Sepsis-related Organ Failure Score criteria, 
the diagnosis of respiratory failure is based on the ratio of arte-
rial oxygen tension (PaO2) to fractional inspired oxygen (FiO2) 
< 200 mmHg. Disease severity was assessed by Acute Physiol-
ogy and Chronic Health Evaluation II (APACHE II) score within 
72 hr after the occurrence of symptoms associated with Aeromo-
nas bacteremia. Acid-suppressant therapy was defined as use 
of proton pump inhibitors or histamine H2 blockers for more 
than 7 days within 4 weeks before onset of the symptoms asso-
ciated with Aeromonas bacteremia.
Species identification and antimicrobial susceptibility
Blood samples were tested daily for microbial growth by the 
BACTEC 9240 (BD, Diagnostic Instrument Systems, Spark, MD, 
USA). Gram-negative bacilli from blood culture bottles were 
identified as Aeromonas species by positive oxidase reaction, 
no growth on thiosulfate-citrate-bile-sucrose agar, growth on 
MacConkey agar, and resistance to the vibriostatic compound 
O/129. Biochemical profiles with the Vitek II system (bioMéri-
eux, Lyon, France), BD-Phoenix system (BD Diagnostic Instru-
ment Systems) or API-20NE system (bioMérieux) were utilized 
for identification of Aeromonas species. Additional tests for API-
20NE system included hydrolysis of esculin and gas production 
from glucose fermentation. Additional tests for Vitek II system or 
BD-Phoenix system included hydrolysis of esculin, Voges-Pros-
kauer reaction, acid production from sucrose fermentation, or-
nithine decarboxylase, acid from arabinose fermentation, and 
arginine dihydrolase production.
  In vitro antimicrobial susceptibilities of Aeromonas isolates 
were tested using the Kirby-Bauer disk-diffusion method, or au-
tomated methods (Vitek II system or the BD-Phoenix system). 
Antibiotics selected for testing included ampicillin, amikacin, 
cefazolin, gentamicin, cefmetazole, ceftriaxone, cefuroxime, cip-
rofloxacin, imipenem, flomoxef, cefpirome, ceftazidime, sulfa-
methoxazole/trimethoprim, aztreonam, ticarcillin/clavulanic 
acid, and piperacillin/tazobactam. The breakpoint concentra-
tions for interpretation were in accordance with Clinical and 
Laboratory Standards Institute (13).
Statistical analyses
SPSS v. 11.5 for MS Windows software (SPSS, Chicago, IL, USA) 
software was used for statistical analyses. Pearson’s chi-square 
test was used to examine nominal data, and one-way ANOVA 
was used for continuous data. All tests were two-sided and a P 
value of  ≤ 0.05 was considered significant.
Ethics statement
This study was approved by the institutional review board of Bud-
dhist Dalin Tzu Chi General Hospital (IRB No. B09801017). In-
formed consent was exempted by the board.
RESULTS
There were 154 patients with monomicrobial Aeromonas bac-
teremia. The mean age was 58 yr (range, 24 to 92 yr) and the over-
all duration of hospitalization was 15 days (range, 1-82). There 
were 112 (73%) male patients and 43 (28%) patients with health-
care-associated bacteremias. There were 63 (41%) patients re-
ceiving acid-suppressant therapy. Liver cirrhosis was most com-
mon underlying disease (58%), followed by diabetes mellitus 
(28%) and solid cancer (26%). There were 126 (82%) patients 
with fever, 107 (69%) patients with thrombocytopenia, and only 
40 (26%) patients with leukocytosis. Of the 87 (56%) patients with 
A. hydrophila bacteremia, one presented with acute cholangitis, 
one with spontaneous bacterial peritonitis, two with traumatic 
wound infections, two with urosepsis, four with necrotizing fas-
ciitis, and the others with primary bacteremia. Of the 45 (29%) 
patients with A. veronii biovar sobria bacteremia, one present-
ed with urosepsis, one with spontaneous bacterial peritonitis, 
one with necrotizing fasciitis, one with meningitis and the oth-
ers with primary bacteremia. Of the 22 (14%) patients with A. 
caviae bacteremia, one patient presented with acute cholecys-
titis, one with traumatic wound infection, one with lung abscess 
and the others with primary bacteremia. There were 55 patients 
who died during hospitalization. Three patients with A. hydroph-
ila bacteremia and one patient with A. caviae bacteremia sur-
vived more than 30 days after onset of Aeromonas bacteremia. 
Their deaths were considered not to be associated with Aeromo-
nas bacteremia. One died due to hepatoma rupture, another due Chuang H-C, et al.  •  Aeromonas Bacteremia
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to esophageal veins bleeding, and the others due to septic shock 
caused by other pathogens. The remaining 51 patients’ deaths 
were attributed to Aeromonas bacteremia.
  Table 1 summarizes clinical presentations of the monomi-
crobial bacteremias caused by A. hydrophila, A. veroni biovar 
sobria, and A. caviae. A. caviae was more associated with health-
care-associated bacteremia than A. hydrophlia and A. veronii 
biovar sobria. However, A. veronii biovar sobria and A. hydroph-
ila were more associated with the cirrhotic patients than A. cavi-
ae. Thrombocytopenia and shock were more common in A. ve-
ronii biovar sobria bacteremia and A. hydrophila bacteremia 
than A. caviae bacteremia. The APACHE II scores and mortality 
of A. hydrophila and A. veronii biovar sobria bacteremia were 
higher than A. caviae bacteremia. 
  Of the 87 A. hydrophila isolates, 61 were identified mainly by 
API-20NE system, 17 by Vitek II system, and 9 by BD-Phoenix 
system. Of the 45 A. veronii biovar sobria isolates, 34 were iden-
tified mainly by API-20NE system, 5 by Vitek II system, and 6 by 
BD-Phoenix system. Of the 22 A. caviae isolates, 16 were identi-
fied mainly by API-20NE system, 3 by Vitek II system, and 3 by 
BD-Phoenix system. In vitro antimicrobial susceptibilities of dif-
ferent Aeromonas species were listed in Table 2. More A. veronii 
biovar sobria isolates were susceptible to cefazolin and flomoxef 
than the other Aeromonas species. Less A. caviae isolates were 
susceptible to sulfamethoxazole/trimethoprim than the other 
Aeromonas species.
  Univariate analyses for risk factors of bacteremia-associated 
mortalities were listed in Table 3. In A. hydrophila bacteremia, 
thrombocytopenia, diarrhea, APACHE II score  > 20 points, and 
adequate empirical antibiotics were risk factors for bacteremia-
associated mortality. The four factors were included for multivar-
iate logistic regression analysis. Only APACHE II score was the 
independent factor for survival (odds ratio: 22.501; P < 0.001). 
In A. veronii biovar sobria bacteremia, APACHE II score was sig-
nificant risk factor for bacteremia-associated mortality. Only one 
77-yr-old woman with community-acquired A. caviae bactere-
mia died. She had liver cirrhosis, diabetes mellitus, and chronic 
usage of acid-suppressant therapy. She presented with fever, 
dyspnea, septic shock, and thrombocytopenia with 31 points of 
APACHE II score at admission. She was treated with levofloxa-
cin, which was considered as an adequate empirical antibiotics 
according in vitro antimicrobial susceptibility. However, she still 
died after 24-day hospitalization. Fig. 1 showed box plots of the 
distributions of APACHE II scores for monomicrobial Aeromo-
nas bacteremia stratified by different Aeromonas species and 
survival.
 
DISCUSSION
Commercial phenotyping systems used routinely in clinical mi- Table 1. Different clinical presentations among A. hydrophila, A. caviae and A. veronii 
biovar sobria bacteremia
Parameters
A. hydrophila 
(n = 87)
A. veronii 
biovar sobria 
(n = 45)
A. caviae
(n = 22)
P value
Age, mean years ± SD 58.8 ± 14.3 56.3 ± 16.0 59.4 ± 16.4 0.600
Gender (male), No. (%) 65 (75) 33 (73) 14 (64) 0.578
Healthcare-associated 
   infection, No. (%)
26 (30)   7 (16) 10 (45) 0.031*
Underlying disease
   Post-surgery, No. (%)
   Solid cancer, No. (%)
   Diabetes mellitus, No. (%)
   Cirrhosis, No. (%)
   Neutropenia, No. (%)
   Acid-suppressant therapy
 
12 (14)
19 (22)
27 (31)
54 (62)
3 (3)
39 (45)
 
  6 (13)
13 (29)
  9 (20)
29 (64)
  5 (11)
20 (44)
 
  6 (27)
  8 (36)
  7 (32)
  6 (27)
1 (5)
  4 (18)
 
0.263
0.332
0.370
0.007*
0.198
0.064
Symptoms and signs
   Leukocytosis, No. (%)
   Thrombocytopenia, No. (%)
   Fever, No. (%)
   Shock, No. (%)
   Diarrhea, No. (%)
   Abdominal pain, No. (%)
   Acute renal failure, No. (%)
   Acute respiratory failure,  
      No. (%)
 
23 (26)
58 (67)
69 (79)
35 (40)
7 (8)
65 (75)
22 (25)
12 (14)
 
14 (31)
39 (87)
38 (84)
21 (47)
  5 (11)
16 (36)
10 (22)
  8 (18)
 
  3 (14)
10 (45)
19 (86)
2 (9)
  3 (14)
  5 (23)
2 (9)
0 (0)
 
0.306
0.002*
0.643
0.009*
0.684
0.578
0.262
0.120
APACHE II score, median  
   points (IQR)
14 (16) 16 (16) 7 (5) 0.002*
Prognosis
   Death attributable to 
   Aeromonas bacteremia, No. (%)
31 (36) 19 (42) 1 (5) 0.007*
APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation; IQR, 
interquartile range. *P < 0.05.
Table 2. In vitro antimicrobial susceptibilities of different Aeromonas species
Antimicrobial agents
A. hydrophila 
(n = 87)  
Susceptible/ 
tested isolates 
(%)
A. veronii 
biovar sobria 
(n = 45)  
Susceptible/ 
tested isolates 
(%)
A. caviae 
(n = 22) 
Susceptible/ 
tested isolates 
(%)
P value
Gentamicin 83/87 (95) 45/45 (100) 21/22 (95) 0.344
Amikacin 86/87 (99) 44/44 (100) 22/22 (100) 0.679
Cefazolin 7/87 (8) 17/45 (38) 0/22 (0) < 0.001*
Cefuroxime 55/72 (76) 31/39 (79) 15/20 (75) 0.906
Cefmetazole 32/57 (56) 22/29 (76) 7/14 (50) 0.137
Flomoxef 34/59 (58) 24/28 (86) 7/14 (50) 0.018
†
Ceftriaxone 81/87 (93) 45/45 (100) 20/22 (91) 0.161
Ceftazidime 47/50 (94) 35/35 (100) 18/19 (95) 0.137
Cefpirome 54/57 (95) 29/29 (100) 14/14 (100) 0.311
Aztreonam 53/54 (98) 38/38 (100) 19/19 (100) 0.345
Ticarcillin/
   clavulanic acid
26/31 (84) 23/30 (77) 10/17 (59) 0.152
Piperacillin/tazobactam 46/48 (96) 35/35 (100) 19/21 (90) 0.198
Imipenem 85/86 (99) 44/45 (98) 22/22 (100) 0.742
Ciprofloxacin 74/79 (94) 40/40 (100) 21/22 (95) 0.270
Sulfamethoxazole/
   Trimethoprim
29/35 (83) 30/32 (94) 9/19 (47) < 0.001
‡
Ampicillin 1/87 (1) 0/45 (0) 0/22 (0) 0.679
*More isolates of A. veronii biovar sobria were susceptible to cefazolin than A. hydroph-
ila and A. caviae; 
†More isolates of A. veronii biovar sobria were susceptible to flo-
moxef than A. hydrophila and A. caviae; 
‡Less isolates of A. caviae were susceptible 
to sulfamethoxazole/trimethoprim than A. hydrophila and A. veronii biovar sobria.Chuang H-C, et al.  •  Aeromonas Bacteremia
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crobiology laboratories are not exactly correct for identification 
of aeromonads (14, 15). Lamy and his coworkers compared 6 
commercial systems for identifying clinical Aeromonas isolates 
(16). The accuracy of API-20NE system was good for A. hydroph-
ila and A. veronii but not for A. caviae. The accuracy of Vitek II 
system for A. hydrophila and A. caviae was good but not for A. 
veronii. The accuracy of BD-Phoenix system for A. caviae and A. 
veronii was good but not for A. hydrophila. Additional tests, like 
esculin hydrolysis, gas production from glucose, Voges-Proskau-
er reaction, ornithine decarboxylase, and arginine dihydrolase 
production are necessary for confirmation of Aeromonas spe-
cies identified by the commercial systems. However, their accu-
racy of identification is still not compatible with the molecular 
method. In the present study, large sample size alleviated this 
bias and complementary effect of these three commercial sys-
tems can decrease the extreme deviation caused by single com-
mercial system.
  The case mortality among patients with Aeromonas bactere-
mia in the literature ranges from 24%-63% (2-5, 17-22). Clinical 
presentations among different Aeromonas species were rarely 
discussed due to limited cases. In a study including 104 episodes, 
Aeromonas species was divided into hydrophila and non-hy-
drophila and the resulting fatalities were 35.5% (22/62) and 23.8% 
(10/42) respectively (2). In another report including 59 episodes, 
the mortalities caused by A. hydrophila, A. veronii biovar sobria, 
and A. caviae are 33% (13/40), 56% (5/9), and 17% (1/6) respec-
tively (22). However, this tendency could not be noted in another 
report, in which Aeromonas-associated polymicrobial bactere-
mia was not excluded (4). The present study only included mono-
microbial Aeromonas bacteremia and proved that the mortality 
of A. caviae bacteremia was lower than A. hydrophila bactere-
mia or A. veronii biovar sobria bacteremia.
  Different Aeromonas species showed different virulence fac-
tors in immunocompromised mouse models (23). Majority of 
Table 3. Univariate analyses of risk factors of bacteremia-associated mortalities in patients with monomicrobial bacteremia caused by different Aeromonas species
Variables
A. hydrophila (n = 87) A. veroni bioar sobria (n = 45)
Survival (n = 56) Death (n = 31) P value Survival (n = 26) Death (n = 19) P value
Age  ≥ 65 yr, No. (%) 23 (41) 10 (32) 0.561 7 (27) 7 (37) 0.701
Gender (male), No. (%) 42 (75) 23 (74) 1.000 17 (65) 16 (84) 0.191
Healthcare-associated infection, No. (%) 18 (32) 8 (26) 0.629 3 (12) 4 (21) 0.433
Post-surgery, No. (%) 6 (11) 6 (19) 0.334 4 (15) 2 (11) 1.000
Solid cancer, No. (%) 13 (23) 6 (19) 0.884 10 (38) 3 (16) 0.185
Diabetes mellitus, No. (%) 14 (25) 13 (42) 0.164 7 (27) 2 (11) 0.264
Cirrhosis, No. (%) 32 (57) 22 (71) 0.252 17 (65) 12 (63) 1.000
Neutropenia, No. (%) 1 (2) 2 (6) 0.288 2 (8) 3 (16) 0.636
Acid-suppressant therapy, No. (%) 27 (48) 12 (39) 0.530 12 (46) 8 (42) 1.000
Thrombocytopenia, No. (%) 31 (55) 27 (87) 0.006* 22 (85) 17 (89) 1.000
Diarrhea, No. (%) 7 (13) 0 (0) 0.047* 3 (12) 2 (11) 1.000
Abdominal pain, No. (%) 17 (30) 5 (16) 0.228 12 (46) 4 (21) 0.155
APACHE II score  ≥ 20 points, No. (%) 5 (9) 23 (74) < 0.001* 2 (8) 17 (89) < 0.001*
Adequate empirical antibiotics, No. (%) 56 (100) 23 (74) < 0.001* 25 (96) 14 (74) 0.720
APACHE, Acute Physiology and Chronic Health Evaluation. *P < 0.05. 
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Fig. 1. Box plots of Acute Physiology and Chronic Health Evaluation II (APACHE II) scores distributions for A. hydrophila, A. veronii biovar sobria, and A. caviae bacteremia (A) 
and box plots of APACHE II scores distributions for survivals and deaths in different Aeromonas groups (B). Chuang H-C, et al.  •  Aeromonas Bacteremia
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A. hydrophila and A. veronii biovar sobria isolates were capable 
of persistent colonization but A. caviae isolates was not. In vitro 
study showed that A. caviae isolates, unlike other Aeromonas 
isolates were less toxic to HEp-2 cell. However, most of Aeromo-
nas isolates used for these studies were from the natural environ-
ment and the virulence factors of Aeromonas species from in-
fected hosts and natural environments were different (24). Only 
a study showed the virulence factors from the bacteremia-asso-
ciated Aeromonas isolates (12). The genes for cytotoxic entero-
toxin were more common in the A. veronii biovar sobria (13/13) 
and A. hydrophila (15/20) isolates than the A. caviae isolates 
(3/14). Cytotoxic enterotoxin could activate mitogen-activated 
protein kinases and induce classical caspase-associated apop-
tosis in murine macrophages (25). Poor macrophage function 
caused by cytotoxic enterotoxin may contribute to severe sepsis. 
Therefore, poor abilities of A. caviae to produce cytotoxic entero-
toxin may be the reason for better prognosis of A. caviae bacte-
remia. However, this opinion should be proved in a further study.
  The patients diagnosed with healthcare-associated Aeromo-
nas bacteremia had been considered to have colonization of 
Aeromonas species in their gastrointestinal tracts before admis-
sion (2). In the previous study, liver cirrhosis was associated with 
community-acquired Aeromonas bacteremia and malignancy 
with healthcare-associated Aeromonas bacteremia (2-4). In the 
present study, we found that A. caviae was more associated with 
healthcare-associated infection and less associated with cirrho-
sis than the other species. This phenomenon may be also due 
to poor abilities of A. caviae to produce cytotoxic enterotoxin. 
Cirrhotic patients have impaired intestinal permeability due to 
intestinal congestion, edema, and local hypoxia due to portal 
hypertension, which creates a good environment for bacterial 
translocation (26-29). However, additional factors for destroy-
ing mucosal barrier are necessary to help bacterial transloca-
tion. Cytotoxic enterotoxin produced by Aeromonas species can 
induce apoptosis of human intestinal epithelial cells and may 
play an important role for bacterial translocation (25). Due to 
poor production of enterotoxin, A. caviae has lower chance to 
cause bacterial translocation in cirrhotic patients than the other 
Aeromonas species. Compared with the cirrhotic patients, the 
cancer patients had more chances to receive surgeries or cyto-
toxic agents during hospitalization, which caused extensive in-
testinal mucosal damage. That may be the reason why A. caviae 
was more associated with healthcare-associated bacteremia.
  In our study, the susceptibility of these microorganisms to tri-
methoprim-sulfamethoxazole, and cefazolin showed inter-spe-
cies variability. These findings agree with previous studies (10, 
11). Besides, we observed that flomoxef was active to only about 
50% isolates of A. caviae and A. hydrophila. Although flomoxef 
belongs to oxyimino-β-lactam and is considered as a kind of ex-
tended-spectrum cephalosporin, traditional extended-spectrum 
cephalosporins are more efficacious for treatment of Aeromon-
as bacteremia. 
  Although there were some limitations from different commer-
cial identifying systems in our study, this study included large 
sample size and showed different clinical presentations of bac-
teremia among A. hydrophila, A. veronii biovar sobria and A. ca-
viae. In conclusion, the severity of A. caviae bacteremia is lower 
than A. hydrophila bacteremia or A. veronii biovar sobria bac-
teremia.
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This study aimed to evaluate the clinical presentations of 154 patients having A. hydrophila, A. veronii biovar sobria or A. caviae 
monomicrobial bacteremia by retrospective methods in Taiwan. The clinical presentation of A. caviae bacteremia was much 
different from A. hydrophila and A. veronii biovar sobria bacteremia. The patients with A. caviae bacteremia had less severity and 
lower mortality than those with A. veronii biovar sobria or A. hydrophila bacteremia.